Assertio Holdings, Inc. (ASRT)

Market Cap	74.68M
Revenue (ttm)	152.07M
Net Income (ttm)	-331.94M
Shares Out	95.12M
EPS (ttm)	-4.67
PE Ratio	n/a
Forward PE	12.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,904,574
Open	0.861
Previous Close	0.866
Day's Range	0.732 - 0.861
52-Week Range	0.739 - 8.010
Beta	1.00
Analysts	Strong Buy
Price Target	3.50 (+345.8%)
Earnings Date	May 6, 2024

About ASRT

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of ag...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 5, 1997
• Employees: 53
• Stock Exchange: NASDAQ
• Ticker Symbol: ASRT

Analyst Forecast

According to 2 analysts, the average rating for ASRT stock is "Strong Buy." The 12-month stock price forecast is $3.5, which is an increase of 345.80% from the latest price.

Price Target

$3.5

(345.80% upside)

Analyst Consensus: Strong Buy